Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Balance Sheet 2011-2026 | BPTS

Annual Balance Sheet Biophytis SA

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -4.01 M -939 K -8.02 M -18.9 M -2.12 M -8.78 M 715 K 420 K -42.9 K -

Long Term Debt

- - - 1.83 M 5.4 M 6.38 M 661 K 820 K 273 K 537 K 330 K 305 K -

Total Non Current Liabilities

- - - 2.02 M 5.54 M 6.57 M 822 K 961 K 428 K 562 K 344 K 319 K -

Total Liabilities

- - - 20.4 M 25.2 M 14.9 M 4.76 M 3.87 M 1.85 M 1.52 M 1.04 M 1.08 M -

Retained Earnings

- - - -17.1 M -17.8 M -14 M -11.4 M -7.95 M -3.29 M -709 K -522 K - -

Total Assets

12 M 22 M 34.9 M 27.2 M 17.7 M 21.9 M 25.9 M 8.39 M 13.5 M 387 K 628 K 1.21 M -

Cash and Cash Equivalents

5.57 M 11.1 M 23.9 M 5.85 M 6.34 M 14.4 M 19.9 M - - - - - -

Book Value

- - 34.9 M 6.83 M -7.53 M 7.01 M 21.2 M 4.52 M 11.7 M -1.13 M -409 K 126 K -

Total Shareholders Equity

- - - 2.27 M -8.28 M 7.01 M 21.2 M - - - - - -

All numbers in EUR currency

Quarterly Balance Sheet Biophytis SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Total Non Current Liabilities

- - - - 7.41 M - - - 2.02 M - - - 5.54 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 36.3 M - - - 27.2 M - - - 17.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 23.9 M - - - 5.85 M - - - 6.34 M - - - 14.4 M - - - 19.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 36.3 M - - - 27.2 M - - - 17.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 5.7 M - - - 2.27 M - - - -8.28 M - - - 7.01 M - - - 21.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Balance Sheet is a fundamental financial report of Biophytis SA, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.9 -2.33 % $ 6.62 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.96 -0.68 % $ 3.64 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 1.02 -0.49 % $ 428 M israelIsrael
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 6.4 4.4 % $ 63.3 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.41 1.9 % $ 1 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.26 3.72 % $ 1.62 B australiaAustralia
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 105.46 -0.09 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 0.25 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.26 1.75 % $ 2.96 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 -5.88 % $ 383 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.06 -3.64 % $ 12.9 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.95 -3.28 % $ 296 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.91 -1.36 % $ 4.79 M israelIsrael
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA